title: Clinical trials for neurodevelopmental disorders: At a therapeutic frontier.
abstract: A well-powered clinical trial that failed to replicate promising results in animal models of fragile X syndrome yields important lessons for clinical trial design (Berry-Kravis et al., this issue).
authors.affiliation: Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA 90095-17610, USA.
authors.forename: Shafali S
authors.initials: SS
authors.lastname: Jeste
authors.affiliation: Center for Autism Research and Treatment, Semel Institute, and Neurogenetics Program, Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095-1761, USA. dhg@mednet.ucla.edu.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Geschwind
mesh_terms: D000818:Animals; D051860:Fragile X Messenger Ribonucleoprotein 1; D005600:Fragile X Syndrome / Q000188:drug therapy*; D006801:Humans; D065886:Neurodevelopmental Disorders
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1